Affimed Announced Saturday, In 17 EGFR Wild-type NSCLC Patients Who Failed Chemotherapy And PD-1/PD-l1, AFM24 Plus Atezolizumab Achieved 4 Objective Responses; 3 Of 4 Responses Were Ongoing For More Than 7 Months, Progression Free Survival Was 5.9 Months
Portfolio Pulse from Charles Gross
Affimed announced that in a study of 17 EGFR wild-type NSCLC patients who failed chemotherapy and PD-1/PD-L1 treatments, AFM24 plus Atezolizumab achieved 4 objective responses. Three of these responses were ongoing for more than 7 months, and the progression-free survival was 5.9 months.
June 02, 2024 | 6:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Affimed's AFM24 plus Atezolizumab showed promising results in a study of NSCLC patients, achieving 4 objective responses and a progression-free survival of 5.9 months.
The positive results from the study indicate potential efficacy of AFM24 plus Atezolizumab in treating NSCLC patients, which could boost investor confidence and positively impact Affimed's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100